FDA Issues New Guidances Regarding Its Preliminary Review of 510(k) Notices and PMA Applications

more+
less-

On December 31, 2012, FDA issued two final guidances that replace prior guidances related to the review of premarket submissions: “Refuse to Accept Policies for 510(k)s” and “Acceptance and Filing Reviews for Premarket Approval Applications (PMAs)” (hereinafter referred to as the 510(k) RTA Guidance and PMA Acceptance and Filing Guidance, respectively). Both guidances went into effect on December 31, 2012 and were issued to help FDA meet its performance goals under the Medical Device User Fee Amendments of 2012 (MDUFA III). We expect FDA to apply the 510(k) RTA and PMA Acceptance and Filing criteria stringently, at least in the near future, resulting in a greater number of submissions not being accepted and/or filed. Therefore, we recommend companies pay close attention to the RTA and Acceptance and Filing criteria and prepare their submissions accordingly.

This client alert highlights key aspects of these guidance documents. Copies of the complete guidance documents are available at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Guidanc eDocuments/ucm162707.htm.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  510(k) RTA, FDA, Medical Devices, PMA Acceptance and Filing Guidance, Premarket Approval Applications

Published In: Administrative Agency Updates, General Business Updates, Health Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© King & Spalding | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »